SCHEMBL4715657

SCHEMBL4715657

O=[N+]([O-])c1cccc(-c2cc(Nc3cccc4cnccc34)ncn2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 9/20 0.53
CDK9 P50750 9/20 0.53
PLK1 P53350 1/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
ABL1 P00519 2/20 0.44
BCR P11274 2/20 0.44
PRKCA P17252 2/20 0.44
PDE4A P27815 1/20 0.44
PDE4C Q08493 1/20 0.44
PDE4D Q08499 1/20 0.44
EGFR P00533 1/20 0.44
SRC P12931 1/20 0.44
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
RAF1 P04049 1/20 0.42
BRAF P15056 1/20 0.42
CYP1A2 P05177 1/20 0.40
ABCG2 Q9UNQ0 1/20 0.40
PDE4B Q07343 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716052 0.84 PDE4B (0.51) ABL1BCRCYP1A2PDE4B
SCHEMBL4718686 0.82 ALDH1A1 (0.48) CCNT1CDK9CYP1A2PDE4B
SCHEMBL4715734 0.82 TRPV1 (0.45) ABL1BCREGFRRAF1BRAF
SCHEMBL4718692 0.82 TRPV1 (0.49) ABL1BCRCYP1A2PDE4B
SCHEMBL4718622 0.81 PDE4B (0.41) CCNT1CDK9ABL1BCRCYP1A2
SCHEMBL4718454 0.81 MAPK1 (0.45) ABL1BCRPRKCACYP1A2PDE4B
SCHEMBL4719637 0.81 TRPV1 (0.48) CYP1A2PDE4B
SCHEMBL4718526 0.79 TRPV1 (0.41) CYP1A2PDE4B
SCHEMBL4715943 0.79 TRPV1 (0.55) ABL1BCR
SCHEMBL4717106 0.78 TRPV1 (0.43) PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7442701-B2 Amino-heterocycles as VR-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2008-10-28 US disclosed
EP-1562934-B1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME (GB) 2008-03-26 EP disclosed
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain MERCK SHARP & DOHME LTD. (GB) 2006-02-23 US disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040947-A1 Amino-heterocycles as vr-1 antagonists for treating pain OPRL1, CNR1, GPR6 CCNT1 1668/4885CDK9 2639/4885PLK1 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.